DE60335610D1 - Neoplasma-spezifische antikörper und deren verwendungen - Google Patents

Neoplasma-spezifische antikörper und deren verwendungen

Info

Publication number
DE60335610D1
DE60335610D1 DE60335610T DE60335610T DE60335610D1 DE 60335610 D1 DE60335610 D1 DE 60335610D1 DE 60335610 T DE60335610 T DE 60335610T DE 60335610 T DE60335610 T DE 60335610T DE 60335610 D1 DE60335610 D1 DE 60335610D1
Authority
DE
Germany
Prior art keywords
neoplasma
specific antibodies
neoplasms
diagnosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335610T
Other languages
English (en)
Inventor
Heinz Peter Vollmers
Hans Konrad Mueller-Hermelink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patrys Ltd
Original Assignee
Patrys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrys Ltd filed Critical Patrys Ltd
Priority to DE60335610T priority Critical patent/DE60335610D1/de
Application granted granted Critical
Publication of DE60335610D1 publication Critical patent/DE60335610D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60335610T 2002-03-09 2003-03-10 Neoplasma-spezifische antikörper und deren verwendungen Expired - Lifetime DE60335610D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60335610T DE60335610D1 (de) 2002-03-09 2003-03-10 Neoplasma-spezifische antikörper und deren verwendungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10210427A DE10210427A1 (de) 2002-03-09 2002-03-09 Humaner monoklonaler Antikörper
DE60335610T DE60335610D1 (de) 2002-03-09 2003-03-10 Neoplasma-spezifische antikörper und deren verwendungen
PCT/IB2003/001335 WO2003076472A2 (en) 2002-03-09 2003-03-10 Neoplasm specific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DE60335610D1 true DE60335610D1 (de) 2011-02-17

Family

ID=27797631

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10210427A Withdrawn DE10210427A1 (de) 2002-03-09 2002-03-09 Humaner monoklonaler Antikörper
DE60335610T Expired - Lifetime DE60335610D1 (de) 2002-03-09 2003-03-10 Neoplasma-spezifische antikörper und deren verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10210427A Withdrawn DE10210427A1 (de) 2002-03-09 2002-03-09 Humaner monoklonaler Antikörper

Country Status (8)

Country Link
US (2) US20050208056A1 (de)
EP (2) EP2292666A3 (de)
AT (1) ATE494307T1 (de)
AU (1) AU2003214537B2 (de)
CA (1) CA2478116A1 (de)
DE (2) DE10210427A1 (de)
ES (1) ES2359052T3 (de)
WO (1) WO2003076472A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160029A0 (en) 2001-07-24 2004-06-20 Receptor, the use thereof, and mouse antibodies
DE10210427A1 (de) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
EP2322559A3 (de) * 2002-07-04 2011-08-03 Patrys Limited Neoplasma-spezifische Antikörper und deren Verwendungen
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2004097019A1 (ja) * 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
NZ577824A (en) * 2003-11-12 2010-10-29 Patrys Ltd Methods of identifying neoplasm-specific antibodies and uses thereof
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
WO2006089002A2 (en) * 2005-02-15 2006-08-24 Yale University Method for high throughput screening for antibodies and proteins inducing apoptosis
WO2009033013A1 (en) * 2007-09-05 2009-03-12 Nurit Rachamim Antibodies against flagellin and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
DE3722647A1 (de) 1987-07-09 1989-01-19 Gerhard Ohlenschlaeger Galenische verwendung eines tripeptids als arzneimittel
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU4982097A (en) * 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
US7049132B1 (en) * 1999-06-28 2006-05-23 University Of Southern California Stress-responsive induction of a therapeutic agent and methods of use
US6677442B1 (en) * 1999-10-29 2004-01-13 University Of Kentucky Research Foundation Nucleic acid encoding human REV1 protein
MXPA02008144A (es) * 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
DE10210427A1 (de) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
WO2005001052A2 (en) * 2003-06-06 2005-01-06 University Of Massachusetts Modulation of apoptosis

Also Published As

Publication number Publication date
EP1485415B1 (de) 2011-01-05
ATE494307T1 (de) 2011-01-15
AU2003214537A1 (en) 2003-09-22
EP2292666A2 (de) 2011-03-09
DE10210427A1 (de) 2003-10-09
WO2003076472A2 (en) 2003-09-18
AU2003214537B2 (en) 2010-02-18
EP1485415A2 (de) 2004-12-15
US20050208056A1 (en) 2005-09-22
CA2478116A1 (en) 2003-09-18
US20110076763A1 (en) 2011-03-31
ES2359052T3 (es) 2011-05-18
EP2292666A3 (de) 2011-06-08
WO2003076472A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
DE60305200D1 (de) Aminocyclohexylether-verbindungen und deren verwendung
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE378356T1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
ATE458717T1 (de) Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide
DE60235632D1 (de) Bicyclische verbindung, deren herstellung und verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
DE50212604D1 (de) Makrocyclische metallkomplexe und deren verwendung zur herstellung von konjugaten mit biomolekülen
CL2004000964A1 (es) Uso de compuestos derivados de piperazina 1,4 disustituida, util en el tratamiento de trastornos delusorios, psicosis y trastornos depresivos.
SE9904377D0 (sv) Pharmaceutical combinations
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE365748T1 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE60204755D1 (de) "3,7-diazabicyclo(3.3.0)octane und deren verwendung bei der behandlung von herzrhythmusstörungen"
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE362490T1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE602004021477D1 (de) Kondensierte heterocyclen und deren verwendungen
WO2004081027A3 (en) Neoplasm specific antibodies and uses thereof